The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-01

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

NCT03971162

Myopic Choroidal Neovascularisation

COMPLETED NA

Intravitreal Conbercept for Idiopathic Choroidal Neovascularization

NCT02857517

Idiopathic Choroidal Neovascularization

UNKNOWN PHASE2

Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization

NCT06243406

Choroidal Neovascularization

NOT_YET_RECRUITING

Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma

NCT03973125

Circumscribed Choroidal Haemangioma

UNKNOWN EARLY_PHASE1

Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy

NCT01854593

Proliferative Diabetic Retinopathy Diabetic Traction Retinal Detachment Vitreous Hemorrhage

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，Its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. The intravitreal injection of anti-VEGF agent has shown its therapeutic potential for the early stage of NVG, but not for the late stage. Intracameral injection maybe used as an alternative way for administration. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neovascular Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intracameral injection

Intracameral injection of conbercept for the treatment of NVG

Group Type EXPERIMENTAL

Intracameral injection

Intervention Type PROCEDURE

Intracameral Conbercept injection for the treatment of NVG

Intravitreal injection

Intravitreal injection of conbercept for the treatment of NVG

Group Type ACTIVE_COMPARATOR

Intravitreal injection

Intervention Type PROCEDURE

Intravitreal Conbercept injection for the treatment of NVG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intracameral injection

Intracameral Conbercept injection for the treatment of NVG

Intervention Type PROCEDURE

Intravitreal injection

Intravitreal Conbercept injection for the treatment of NVG

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a diagnosis of neovascular glaucoma (Stage 1-2-3)
* Individuals who are ages 20-80 years old; male or female of chinese
* Visual acuity of light perception or better in the study eye
* Willing and able to comply with clinic visits and study-related procedures
* Provide signed informed consent

Exclusion Criteria

* Use of intraocular anti-VEGF agents in the study eye in the past 3 months.
* Active ocular or periocular infection in the study eye
* Uncontrolled Blood Pressure
* Thromboembolism
* Congestive Heart Failure
* Renal Failure
* History of myocardial infarction
* History of Stroke
* Pregnant or breast-feeding women
* Participation in another simultaneous medical investigator or trial

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No